Gilead’s India Patent Snag May Spur Low-Cost Sovaldi Copies

Updated on

The Indian patent office’s rejection of a key patent claim for Gilead Sciences Inc.’s Hepatitis C treatment Sovaldi may pave the way for more low-cost copies in the country, potentially aiding local companies including Natco Pharma Ltd.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.